Ketricin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ketricin

Property Description
Active ingredient Triamcinolone Acetonide
Primary Form Tablet (for systemic use)
Pharmacological Class Corticosteroid / Glucocorticoid
General Purpose Relief from inflammation and immune suppression
Origin Synthetic (fluorinated derivative)

Ketricin is a designated prescription-only medicine that utilizes the single active ingredient, Triamcinolone Acetonide, and is classified as a potent glucocorticoid primarily intended for systemic use. As a single-ingredient product, the therapeutic identity of the brand is defined entirely by this well-recognized compound.


What is Ketricin and its Active Ingredient?

Ketricin is a specific pharmaceutical product most commonly formulated as a tablet for oral administration, designed to deliver a powerful anti-inflammatory effect throughout the body. Its therapeutic action is derived exclusively from Triamcinolone Acetonide, which is a halogenated, synthetic derivative of triamcinolone. This substance is chemically engineered, distinguishing it as a synthetic compound derived from the body's natural steroid hormone, cortisol. While Ketricin is designated for oral use, the compound Triamcinolone Acetonide is also globally prevalent in topical preparations like creams and for localized injections.


What Type of Medicine is Ketricin?

Ketricin belongs to the corticosteroid family and is specifically categorized as a potent glucocorticoid, a classification applied to this class of steroidal anti-inflammatory drugs. The oral tablet dosage form allows for systemic delivery, enabling the active substance to be absorbed into the bloodstream to affect various tissues and systems within the body, which is suitable for generalized inflammatory scenarios. Glucocorticoids are an effective treatment against inflammation and autoimmune responses, supporting the general understanding of the drug's purpose.


What is the General Purpose of This Drug?

The primary general purpose of Ketricin is to provide robust relief from inflammation and act as an immunosuppressant to control overactive immune responses. The drug helps stabilize the body's reaction to irritation and other triggers by effectively blocking the molecular pathways that lead to redness, swelling, and discomfort.

Regulatory References

  1. Glucocorticoids (NCBI/NIH Classification)

What side effects are possible with Ketricin?

Possible Side Effects and Safety Information

This information is based strictly on the regulatory safety profile of Ketricin (Cetirizine Hydrochloride) as documented by governmental health authorities.


Documented Adverse Reactions

The most commonly reported side effects typically involve the central nervous system and general bodily fatigue, categorized by frequency:

Frequency Side Effects (Examples)
Common (up to 1 in 10) Drowsiness (somnolence), Headache, Dizziness, Fatigue, Dry mouth
Uncommon (up to 1 in 100) Agitation, Paresthesia (tingling), Diarrhea, Rash, Weakness

System-Organ-Class Groupings

Adverse events are formally classified according to the body system affected. Major system groupings include Nervous System Disorders (e.g., somnolence, headache), Gastrointestinal Disorders (e.g., dry mouth, diarrhea), Skin and Subcutaneous Tissue Disorders (e.g., rash, pruritus), and General Disorders (e.g., fatigue, malaise).

Serious Adverse Reactions

Regulatory documents list rare but clinically significant adverse reactions. These include Anaphylactic Shock (a severe allergic reaction) and Convulsions (seizures), which are documented as very rare events (affecting fewer than 1 in 10,000 people). Hepatic function abnormalities (changes in liver enzyme levels) are also documented as a rare event.

Population-Specific Safety Constraints

Specific cautions and dose adjustments are mandated in the official labeling for certain patient groups:

  • Renal and Hepatic Impairment: Dose adjustment is required for patients with moderate to severe renal impairment and for those with hepatic impairment.
  • Pregnancy and Lactation: Use requires caution during pregnancy; the medicine is excreted into breast milk, and caution is advised for use during lactation.

Other Safety-Related Limitations

Caution is advised in patients with a predisposition to urinary retention and in epileptic patients or those at risk of convulsions. Concurrently using Ketricin with alcohol or other CNS depressants is discouraged as it may increase the risk of reduced alertness.

Overdose and Emergency Response

Ketricin Overdose and when to seek help

The official regulatory documentation for systemic glucocorticoids, such as Ketricin (Triamcinolone Acetonide), distinguishes between acute ingestion and chronic overexposure.

Documented Manifestations of Overdose

Acute overdose involving a single large dose is generally not anticipated to cause immediate life-threatening symptoms, though minor gastrointestinal upset may occur. The primary documented concern arises from prolonged, high-dose exposure. This chronic overuse can lead to Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and physiological manifestations consistent with iatrogenic Cushing’s syndrome. These documented signs include hyperglycemia, fluid and electrolyte imbalances, and the abnormal distribution of body fat. In children, systemic toxicity is noted as a greater risk, including HPA axis suppression and the potential for growth retardation.

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose or accidental ingestion. The regulatory guidance mandates contacting a Poison Help hotline for specific instructions. Urgent medical consultation is required if severe systemic effects or life-threatening symptoms, such as collapse or an unusual heartbeat, are observed. There is no specific antidote known for Triamcinolone Acetonide. Treatment is confined to symptomatic and supportive therapy, which may include monitoring of vital signs and laboratory testing. Following chronic overexposure, management involves a gradual, controlled tapering of the drug to prevent symptoms of adrenal insufficiency.

Therapeutic Uses of Ketricin

What Ketricin treats: main uses and benefits

Ketricin is relevant when supportive symptom management is appropriate in clinical settings involving heightened physiological activity. It is applied across domains where short-term, symptomatic assistance is generally needed to support the patient. Triamcinolone tablets are used to help with symptoms related to inflammatory or irritative states in certain forms of arthritis, severe allergies, and asthma.


Managing Systemic Symptoms and Symptom Clusters

the medication helps address symptom clusters that may become intense or disruptive, such as those related to conditions characterized by periods of heightened symptoms (e.g., rheumatoid arthritis), severe allergic reactions, and inflammatory skin conditions. It is relevant for managing symptoms that interfere with daily comfort, and the medication supports patients during difficult episodes by easing distress and assists with maintaining functional stability when symptoms are more noticeable.


Supporting Management of Acute Symptomatic Episodes

Ketricin is often used during phases when symptoms become more noticeable in contexts involving acute or disruptive symptom patterns. It is relevant when symptoms become temporarily overwhelming, and is commonly used to help with symptoms related to physical discomfort (e.g., joint swelling, pain, wheezing, or intense itching) associated with acute or episodic changes. The medication contributes to improved comfort during periods of heightened symptoms and helps patients cope more steadily with symptom fluctuations, offering supportive therapeutic benefit during challenging phases.


Quick Fact: Relief for Inflammation and Immune-Driven Discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ketricin — official regulatory information

Eligibility scope

Classification Populations / Conditions
Populations for whom use is allowed Adults and older adolescents for systemic treatment.
Populations for whom use is not recommended Children on long-term therapy (risk of growth interference); Newborn or preterm infants (due to excipient safety concerns in some formulations).
Populations for whom use is contraindicated Patients with known hypersensitivity to the product; Those with active systemic fungal infections; Patients receiving live virus vaccines at immunosuppressive dosages.
Age-related eligibility rules Pediatric: Long-term use may affect growth and development. Geriatric: Older adults may be more susceptible to adverse effects, requiring close clinical supervision.
Condition-specific eligibility rules Caution is advised for patients with renal insufficiency, hepatic impairment (including cirrhosis), diabetes mellitus, and a history of gastrointestinal disease (e.g., peptic ulcer, diverticulitis).
Pregnancy and lactation eligibility status Pregnancy: Classified as FDA Category C. Use is only permitted if the potential benefit outweighs the documented potential risk to the fetus. Lactation: Systemically administered corticosteroids are secreted into human milk; caution is advised, and use is not recommended when nursing newborns.

Eligibility classifications (high-level)

Classification Severity Regulatory Basis (examples) Eligibility-Context Constraints
Contraindicated FDA Prescribing Information, SmPC Comorbidity-linked (infection), Hypersensitivity-linked, Intervention-linked (vaccines).
Use with Caution NIH MedlinePlus, FDA Label Physiological state-linked (organ function), Disease-linked (metabolic, GI).

Resulting eligibility structure

Official eligibility statements:

  • Contraindicated in patients with known hypersensitivity or active systemic fungal infections.
  • Use is strictly conditional for pregnant patients (Category C), justified only if the therapeutic benefit outweighs the fetal risk.
  • Caution is mandatory in patients with comorbidities like diabetes mellitus or those with impaired hepatic or renal function.

Connection to the overall eligibility profile: Regulatory documents define eligibility for Ketricin by establishing absolute prohibitions for populations with hypersensitivity or active systemic infection, which are non-negotiable exclusions. The profile then mandates conditional use and monitoring for groups with pre-existing conditions and for certain lifecycle stages (pediatrics, pregnancy, older adults), thus controlling the populations permitted to receive the medicine.

What should I know about interactions with other medicines?

Contraindicated and Restricted Combinations

Certain combinations are formally prohibited or restricted based on regulatory documentation. Co-administration with Mifepristone is strictly contraindicated. Live or Live, Attenuated Vaccines are also contraindicated in patients receiving immunosuppressive doses of the corticosteroid.

Pharmacokinetic interactions are defined by the drug's metabolism via the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors (e.g., Ritonavir, Cobicistat-containing products) substantially decreases Ketricin's metabolic clearance, leading to increased systemic exposure and increased risk of effects; this combination should generally be avoided unless closely monitored. Conversely, CYP3A4 inducers (e.g., Rifampicin) may increase clearance.


Pharmacodynamic and Procedural Constraints

The interaction profile includes several pharmacodynamic risks that require specific management. Combining Ketricin with Potassium-Depleting Agents (e.g., diuretics) creates an additive risk for hypokalemia. Co-administration with Nonsteroidal Anti-inflammatory Agents (NSAIDs) or Aspirin increases the risk of gastrointestinal side effects, such as bleeding. For patients with myasthenia gravis, Anticholinesterase Agents must be withdrawn at least 24 hours before initiating Ketricin due to the risk of severe weakness. Additionally, the label notes that combining with Oral Anticoagulants may alter the anticoagulant effect, necessitating monitoring of coagulation indices. The profile also notes that Alcohol may increase gastrointestinal irritation risk.

Mechanism of Action

Ketricin’s mechanism is defined by its single active ingredient, Triamcinolone Acetonide, which modulates core physiological processes via intracellular signaling. The molecule acts as a full agonist, binding to the ubiquitous Intracellular Glucocorticoid Receptor (GR) and initiating its movement into the cell nucleus. This interaction grants the drug access to the cell's genetic machinery.

Once nuclear access is gained, the drug-GR complex executes a dual function: transrepression and transactivation. Transrepression involves physically interfering with master signaling factors like Nuclear Factor-kappa B ( NF-kappa B), which blocks the genetic expression of various pro-inflammatory chemicals. Simultaneously, transactivation promotes the synthesis of anti-inflammatory proteins, such as Annexin A1, which inhibit the activity of the enzyme Phospholipase A2 ( PLA2).

The consequence of this genomic modulation is systemic inhibition of the inflammatory cascade. By blocking both pro-inflammatory cytokine production and the key step for generating eicosanoids (prostaglandins and leukotrienes), the mechanism reduces the generation of chemical signals required for inflammatory reactions. Furthermore, the mechanism reduces the activity and migration of critical immune cells like lymphocytes and macrophages, resulting in reduced activity and migration of inflammatory cells.

Dosage and Administration Information

How Ketricin is Used: Official Administration Guidelines

Ketricin is an oral glucocorticoid, and its administration is governed by explicit instructions to ensure appropriate systemic use. The dosing is highly individualized and requires careful adjustment, as detailed in the prescribing information.


Administration Scope

Instruction Entity Standard Guidelines
Route of administration Oral route for systemic delivery.
Dosing schedule Initial Dose is variable; the Maintenance Dose must be the lowest effective dose determined by gradual reduction.
Timing in relation to meals Must be taken with food or milk to mitigate the risk of gastric irritation.
Preparation requirements Administer orally by swallowing the tablet with a glass of water; no preparation or dilution is required.
Age-group administration rules Pediatric dosing is calculated based on body weight or surface area, with an initial range of 0.11 mg/kg/day to 1.6 mg/kg/day in divided doses.
Missed-dose rules If a dose is missed, take it as soon as possible, unless it is near the next scheduled dose. Do not take double or extra doses.
Special procedural conditions The total daily dose is often taken once daily in the morning to align with the body's natural diurnal cortisol pattern.

Resulting Procedural Structure

Official step sequence:

  • Administer the tablet orally with food or milk and a glass of water.
  • Adjust the schedule to ensure the dose is taken at regular intervals, often as a single dose in the morning.
  • Reduce the dosage incrementally to the lowest effective maintenance level after the initial response is achieved.
  • Taper the dose gradually upon discontinuation, which is required after prolonged use.

This protocol establishes a controlled usage structure where the dose is not fixed and mandates a highly individualized approach based on response. The instructions define the precise conditions for intake (with food/milk) and the required tapering process that dictates the time-dependent administration when discontinuing therapy.

Recent Clinical Evidence

Ketricin: Recent Clinical Evidence

Evidence for Use in Systemic Inflammatory Rheumatic Disorders

Research has explored the role of systemic glucocorticoids like Ketricin in conditions characterized by fluctuating or episodic manifestations, such as rheumatoid arthritis. Available evidence includes short-term Randomized Controlled Trials (RCTs) that focused on patients where study protocols defined the need for a systemic, short-duration intervention. These studies were studied for conditions where outcomes related to physical discomfort (like joint pain and swelling) were measured. The findings describe patterns observed in the short-term, but specific data for Ketricin tablets often have sample sizes that were modest or evidence quality that varies across studies.

Evidence for Use in Severe Allergic and Acute Systemic Conditions

Ketricin was evaluated in research for acute and severe inflammatory and allergic reactions, research examining temporary physiological imbalance, including certain cases of asthma and dermatological disorders. The research includes clinical trials where the active ingredient was evaluated in settings with varying symptom burdens. For conditions like acute asthma, studies monitored outcomes reflecting systemic or functional imbalance, such as changes in pulmonary function values. These studies were generally designed to explore episodes where symptoms become more noticeable, with follow-up durations often lasting days to weeks.

Long-Term Studies and Research Gaps

Most controlled research explores short-term symptom changes over defined time intervals of a few weeks or months; consequently, follow-up durations were limited. Long-term effects are not fully established by the existing controlled evidence, and limited information for long-term outcomes is a recognized gap. Furthermore, comparative evidence is lacking from contemporary trials, and data for special populations, such as certain pediatric cohorts, often remains insufficient when considering the systemic oral form. The lack of comprehensive long-term data for certain subgroups is an acknowledged limitation framed in the regulatory research record.

Key Studies & References

  1. NIH MedlinePlus Drug Information - Triamcinolone
  2. WHO Model List of Essential Medicines: Clinical Guidelines for Systemic Glucocorticoids

Frequently Asked Questions (FAQ)

Common questions about Ketricin (FAQ)

Q: What is the main difference between Ketricin and over-the-counter pain relievers?

Ketricin is formally classified as a potent glucocorticoid and corticosteroid. This is a distinct drug class that works differently in the body than common over-the-counter pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen.

Q: Why is Ketricin only available with a prescription?

Ketricin is classified as a potent medication that requires highly individualized dosing and clinical supervision. This is due to the potential for significant effects on the body, such as suppression of natural hormone production.

Q: How quickly should I expect to feel the effects of Ketricin?

While the individual response varies, studies and regulatory information indicate that the onset of anti-inflammatory action for systemic corticosteroids is generally described as beginning within a few hours of administration.

Q: Does Ketricin cause weight gain?

Official regulatory labeling for this class of medicine includes weight gain and increased appetite among the commonly reported potential effects.

Q: How long does Ketricin stay in your system after the last dose?

The official prescribing information documents a biological half-life for the active ingredient, Triamcinolone Acetonide. This documented pharmacokinetic property helps describe how long its effects remain in the body.

Q: Is it normal to have mild stomach discomfort when first starting Ketricin?

Official administration guidelines state that Ketricin must be taken with food or milk. This is a required measure intended to help reduce the risk of gastric irritation or discomfort.

Q: Are there any specific foods I should avoid while taking Ketricin?

Regulatory cautions associated with the corticosteroid class indicate a need to limit sodium intake and monitor carbohydrate intake. This is due to potential effects on fluid retention and blood sugar levels.

Q: What happens if I stop taking Ketricin suddenly?

Regulatory documents require that the dose be gradually reduced, or tapered, when stopping the medicine, especially after prolonged use. This tapering process is required to support the body in recovering its natural hormone production, as it can be suppressed during Ketricin use.

Q: Does Ketricin affect blood pressure readings?

Regulatory documents include hypertension, or high blood pressure, among the potential effects associated with systemic corticosteroids.

Q: Can taking Ketricin affect the results of lab tests?

Official documentation states that the active ingredient may influence the results of certain laboratory tests. This includes tests for parameters such as blood glucose and thyroid function.

Q: Are there different strengths of Ketricin tablets?

Ketricin is supplied in various tablet strengths. This variety is necessary to accommodate the highly individualized dosing required for this type of medication, as described in the official prescribing information.

Q: Is Ketricin considered a new drug or has it been around for a long time?

The active ingredient, Triamcinolone Acetonide, is a well-established synthetic steroid derivative. This compound has been used in various formulations and globally recognized for many years.

Q: Is there a generic version of Ketricin available?

The active ingredient in Ketricin is Triamcinolone Acetonide. This is a well-known compound for which generic versions exist, subject to local regulatory approval.

Q: Does using Ketricin require regular blood work?

Patients on Ketricin, particularly those on long-term treatment, may be subject to periodic laboratory monitoring based on regulatory guidelines. This monitoring can include checking blood parameters such as glucose and electrolyte levels.

Q: Do cold and flu medicines interact with Ketricin?

Official documents warn that some common ingredients found in cold and flu medicines, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs), may interact. Using them together is associated with an increased risk of gastrointestinal side effects.

Q: Is Ketricin safe to take with common pain relievers like acetaminophen?

Official documents do not list acetaminophen (a common non-NSAID pain reliever) as a specifically restricted combination with Ketricin. However, the label does include warnings against concurrent use with NSAIDs.

Q: What happens if I accidentally take too much Ketricin?

Regulatory information states that acute overdose is rare. However, continued excessive use can lead to systemic effects requiring clinical management.

Q: Can I use Ketricin if I am also taking medication for depression or anxiety?

Official documents describe the potential for interactions with strong CYP3A4 inhibitors or other Central Nervous System (CNS) depressants. This is due to the potential for changes in drug exposure or increased risk of reduced alertness.

Q: Does Ketricin interfere with birth control pills?

Regulatory documents include warnings about the potential for interactions between systemic corticosteroids and oral contraceptives. This interaction may alter drug exposure and require monitoring of hormone levels.

Q: Is Ketricin approved in other countries besides the US?

The active ingredient in Ketricin is globally recognized. Regulatory authorities in other regions, such as the European Union (EMA) and Canada (Health Canada), have approved products containing this same active ingredient.

Q: Is it possible to become dependent on Ketricin?

Prolonged use of Ketricin is associated with the suppression of the body's natural hormones. Because of this, regulatory documents require the drug be gradually reduced (tapered) to support the body in recovering its natural function.

Q: Can Ketricin be crushed or split?

Official administration instructions specify that the tablet should be swallowed whole with water and food or milk. The official labeling does not include instructions for preparing the tablet by crushing or splitting.

Q: What is the typical time frame for the initial course of Ketricin treatment?

The exact duration of treatment is highly individualized and determined by clinical response. Studies and official information indicate that research examined short-term interventions typically lasting days to weeks.

Q: Are patients required to have specific monitoring while on Ketricin?

Regulatory documents state that patients, particularly those on prolonged therapy or with certain conditions, may require specific monitoring. This includes checking growth in children and performing eye examinations.

Q: Is the liquid form of Ketricin more effective than the tablet form?

The current formulation of Ketricin for systemic use, as described in official regulatory documents, is the oral tablet. The effectiveness of non-systemic forms (like liquids or creams) is assessed separately for their intended use.

Q: Are there studies on Ketricin use in people with pre-existing heart conditions?

Official documentation advises caution and close monitoring for patients with certain pre-existing cardiac conditions. This includes conditions such as congestive heart failure and hypertension.

Q: Is Ketricin linked to hair loss?

The official safety profile for systemic corticosteroids includes rare dermatological adverse effects. These potential effects may require further clinical consideration.

Q: What is the official classification of Ketricin (e.g., controlled substance)?

Ketricin is officially classified by regulatory bodies as a prescription-only medicine. It is generally not designated as a controlled substance.

Q: Are there any differences in effectiveness between brand-name Ketricin and its generic alternative?

Regulatory agencies require that a generic alternative be bioequivalent to the brand-name product. This means the generic must act on the body in the same way and achieve the same level of effectiveness.

How should Ketricin be stored and disposed of?

How to Store and Dispose of Ketricin

Ketricin (Triamcinolone) tablets must be stored according to regulatory requirements to ensure product integrity.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature (20 C to 25 C).
Prohibited Keep from freezing; do not expose to excess heat or moisture.
Packaging Store in the original container, keeping it tightly closed.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Ketricin must be disposed of safely. Follow any specific disposal instructions provided on the drug labeling. The preferred method is to use a community drug take-back program. If this option is unavailable, the tablets should be mixed with an unappealing substance, sealed in a container, and discarded in the household trash. Scratch out all personal information on the prescription label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ketricin found in:

A-Z Index: